{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:09:11Z","timestamp":1793372951016,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are a diverse group of hematopoietic stem cell neoplasms associated with an increased risk of hematologic progression to secondary MF or leukemia and cardiovascular disease (CVD). Elevated total cholesterol levels are traditional CVD risk factors. Patients with MPNs may have reduced cholesterol levels, potentially reflecting an underlying hypermetabolic state. The impact of serum total cholesterol on clinical outcomes in patients with MPNs has not yet been evaluated. We performed a multicenter retrospective cohort study of patients with MPNs who had transthoracic echocardiogram (TTE) with available serum lipid levels at time of TTE not on statin therapy. Patients were categorized by total cholesterol level (\u2265150, 120-149, and &amp;lt;120 mg\/dL). Outcomes evaluated were MPN disease progression to secondary MF or acute leukemia, major adverse cardiovascular events, and all-cause mortality. Multivariable competing-risk regression modeling was performed. A total of 305 patients were included of whom 54.4% had total cholesterol \u2265150 mg\/dL, 21.3% had 120 to 149 mg\/dL, and 24.3% had &amp;lt;120 mg\/dL. After a median follow-up of 50.8 months, total cholesterol &amp;lt;120 mg\/dL was associated with increased risk of MPN disease progression (adjusted subhazard ratio, 3.00; 95% confidence interval [CI], 1.36-6.63), heart failure hospitalization (aSHR, 3.76; 95% CI, 1.77-7.96), and all-cause death (adjusted hazard ratio, 1.87; 95% CI, 1.06-3.30) vs \u2265150 mg\/dL. Among patients with MPN, low total cholesterol levels were associated with increased risk of MPN disease progression and death especially among patients with ET or PV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019152","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T20:54:47Z","timestamp":1772657687000},"page":"3746-3755","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms"],"prefix":"10.1182","volume":"10","author":[{"given":"Orly","family":"Leiva","sequence":"first","affiliation":[{"name":"1Gill Heart & Vascular Institute, University of Kentucky College of Medicine, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Soo","sequence":"additional","affiliation":[{"name":"2Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4995-4863","authenticated-orcid":false,"given":"Olivia C.","family":"Liu","sequence":"additional","affiliation":[{"name":"2Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4734-6557","authenticated-orcid":false,"given":"Victor","family":"You","sequence":"additional","affiliation":[{"name":"3Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5239-0676","authenticated-orcid":false,"given":"Andrew","family":"Palmer","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-6794","authenticated-orcid":false,"given":"Justin","family":"Kahla","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Murtaza","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Section of Hematology & Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand","family":"Patel","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Section of Hematology & Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"DeCara","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3987-0647","authenticated-orcid":false,"given":"Patrycja M.","family":"Dubielecka","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Petersen","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-4471","authenticated-orcid":false,"given":"Michelle Hyunju","family":"Lee","sequence":"additional","affiliation":[{"name":"3Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-0117","authenticated-orcid":false,"given":"Joan","family":"How","sequence":"additional","affiliation":[{"name":"7Division of Hematology & Oncology, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"3Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"9","key":"2026052611214471600_bib1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN Clinical Practice Guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2026052611214471600_bib2","first-page":"895","article-title":"Myeloproliferative neoplasms","volume":"377","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026052611214471600_bib3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular disease in myeloproliferative neoplasms: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"11","key":"2026052611214471600_bib4","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"2026052611214471600_bib5","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"2026052611214471600_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9343(81)90212-6","article-title":"Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity","volume":"71","author":"Gilbert","year":"1981","journal-title":"Am J Med"},{"issue":"2","key":"2026052611214471600_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3960\/jslrt.52.85","article-title":"Hypocholesterolemia in patients with polycythemia vera","volume":"52","author":"Fujita","year":"2012","journal-title":"J Clin Exp Hematop"},{"issue":"1","key":"2026052611214471600_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12185-022-03321-z","article-title":"Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes","volume":"116","author":"Yanagisawa","year":"2022","journal-title":"Int J Hematol"},{"issue":"1","key":"2026052611214471600_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-020-00963-6","article-title":"Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116\u2009728 individuals","volume":"13","author":"Pedersen","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2026052611214471600_bib10","first-page":"135","article-title":"Lipoprotein composition in agnogenic myeloid metaplasia","volume":"39","author":"Leglise","year":"1985","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"2026052611214471600_bib11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"20","key":"2026052611214471600_bib12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2026052611214471600_bib13","first-page":"2388","article-title":"Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms","volume":"110","author":"Leiva","year":"2025","journal-title":"Haematologica"},{"issue":"8","key":"2026052611214471600_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017986","article-title":"Impact of echocardiographic probability of pulmonary hypertension on prognosis and outcomes among patients with myeloproliferative neoplasms","volume":"18","author":"Leiva","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"2026052611214471600_bib15","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"2026052611214471600_bib16","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"22","key":"2026052611214471600_bib17","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2026052611214471600_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073636","article-title":"Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases","volume":"23","author":"Buonacera","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026052611214471600_bib19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"2026052611214471600_bib20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-024-00994-z","article-title":"Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study","volume":"14","author":"Larsen","year":"2024","journal-title":"Blood Cancer J"},{"issue":"11","key":"2026052611214471600_bib21","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1007\/s00277-024-06023-0","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as novel prognostic biomarkers in BCR-ABL negative myeloproliferative neoplasms","volume":"103","author":"Cvetkovic","year":"2024","journal-title":"Ann Hematol"},{"issue":"3","key":"2026052611214471600_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1515\/CCLM.1999.059","article-title":"Reduction of circulating cholesterol and apolipoprotein levels during sepsis","volume":"37","author":"Fraunberger","year":"1999","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"2026052611214471600_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081693","article-title":"Lipid and lipoprotein dysregulation in sepsis: clinical and mechanistic insights into chronic critical illness","volume":"10","author":"Barker","year":"2021","journal-title":"J Clin Med"},{"key":"2026052611214471600_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1365015","article-title":"Elevated levels of damage-associated molecular patterns HMGB1 and S100A8\/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis","volume":"15","author":"De Luca","year":"2024","journal-title":"Front Immunol"},{"issue":"26","key":"2026052611214471600_bib25","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","article-title":"Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation","volume":"132","author":"Jacquelin","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026052611214471600_bib26","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41467-022-32927-4","article-title":"Inhibition of interleukin-1beta reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm","volume":"13","author":"Rai","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"2026052611214471600_bib27","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41416-025-03196-x","article-title":"Serum lipid levels and risk of lymphoid malignancies in the UK Biobank study","volume":"133","author":"Hermosa","year":"2025","journal-title":"Br J Cancer"},{"issue":"1","key":"2026052611214471600_bib28","first-page":"143","article-title":"Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis","volume":"29","author":"Alford","year":"2018","journal-title":"Cancer Causes Control"},{"issue":"10","key":"2026052611214471600_bib29","first-page":"1693","article-title":"Erythrocyte membrane fatty acid composition, serum lipids, and non-Hodgkin's lymphoma risk in a nested case-control study: the multiethnic cohort","volume":"23","author":"Morimoto","year":"2012","journal-title":"Cancer Causes Control"},{"issue":"5","key":"2026052611214471600_bib30","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/1055-9965.EPI-19-0803","article-title":"Lipid trait variants and the risk of non-hodgkin lymphoma subtypes: a Mendelian randomization study","volume":"29","author":"Kleinstern","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"2026052611214471600_bib31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.0000200082.58536.e1","article-title":"ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I","volume":"26","author":"Gelissen","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"2026052611214471600_bib32","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study","volume":"7","author":"Tuyet Kristensen","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2026052611214471600_bib33","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1182\/bloodadvances.2025017016","article-title":"Statins enhance the efficacy of pegylated interferon-alpha2 in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"9","author":"Davidsen","year":"2025","journal-title":"Blood Adv"},{"issue":"18","key":"2026052611214471600_bib34","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1002\/cam4.6528","article-title":"Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia","volume":"12","author":"Podoltsev","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"2026052611214471600_bib35","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/bloodadvances.2025018724","article-title":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms","volume":"10","author":"Leiva","year":"2026","journal-title":"Blood Adv"},{"issue":"4","key":"2026052611214471600_bib36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-020-03950-6","article-title":"The impact of statins on the intensity of phlebotomies in polycythemia vera","volume":"99","author":"Krecak","year":"2020","journal-title":"Ann Hematol"},{"issue":"5","key":"2026052611214471600_bib37","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2016.05.043","article-title":"High-output heart failure: a 15-year experience","volume":"68","author":"Reddy","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 1","key":"2026052611214471600_bib38","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood-2024-207586","article-title":"Incidence, risk factors, and prognostic implications of heart failure hospitalizations among patients with myeloproliferative neoplasms","volume":"144","author":"Leiva","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3746\/2521886\/blooda_adv-2025-019152-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3746\/2521886\/blooda_adv-2025-019152-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:21:52Z","timestamp":1779808912000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3746\/566927\/Low-serum-cholesterol-is-a-biomarker-of-advanced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019152","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,26]]}}}